Publications by authors named "Karen A Pekle"
Article Synopsis
- A phase 2 study evaluated a new treatment approach called Car-BiRd for multiple myeloma, combining carfilzomib and dexamethasone for induction, followed by lenalidomide and clarithromycin for consolidation, then lenalidomide maintenance.
- The treatment showed a high overall response rate of 94%, with 35% of patients achieving complete responses, although the results fell short of the study's goal of 55%.
- The regimen resulted in manageable low-grade toxicities and lower hematologic side effects compared to traditional combination therapies, demonstrating effectiveness particularly for patients who are not candidates for transplant.
The addition of clarithromycin enhances the efficacy of lenalidomide plus dexamethasone in treatment-naive multiple myeloma (MM). We conducted a phase 2 trial to evaluate the safety and efficacy of clarithromycin, pomalidomide, and dexamethasone (ClaPd) in relapsed or refractory multiple myeloma (RRMM) with prior lenalidomide exposure. One hundred twenty patients with a median of 5 prior lines of therapy received clarithromycin 500 mg orally twice daily, pomalidomide 4 mg orally on days 1 to 21, and dexamethasone 40 mg orally on days 1, 8, 15, and 22 of a 28-day cycle.
View Article and Find Full Text PDFCarfilzomib and dexamethasone (Kd) has significant activity in relapsed and refractory multiple myeloma. Kd has not previously been evaluated in newly diagnosed multiple myeloma (NDMM). We report a single-arm phase 2 study of 72 patients with NDMM to evaluate the efficacy and tolerability of Kd induction.
View Article and Find Full Text PDF